REGISTER
Upadacitinib Monotherapy Shows Strong Efficacy in Papulopustular Rosacea
The multidimensional efficacy of upadacitinib.

Rosacea is a highly prevalent chronic inflammatory skin disease, and papulopustular rosacea, or PPR, has become a particular focus of clinical attention because of recurrent lesions and the difficulty of treatment. The limitations of traditional regimens in efficacy, safety, and long-term control have made the demand for new therapeutic approaches increasingly urgent.

Recently, a real-world study led by Prof. Jiawen Wu’s team at the Second Affiliated Hospital of Xi’an Jiaotong University and evaluating JAK inhibitor upadacitinib monotherapy for PPR was published in JAAD, one of the leading journals in dermatology, bringing a new breakthrough to the field.

The Limits of Traditional Therapy and the Unmet Clinical Need

Prof. Jiawen Wu said that the traditional treatment system for papulopustular rosacea has clear shortcomings. Topical agents such as metronidazole and azelaic acid remain basic options for mild to moderate disease, but long-term use can cause skin irritation and their efficacy is limited in moderate to severe cases. Oral tetracycline antibiotics such as doxycycline and minocycline are central to systemic treatment, but about 30% of patients develop gastrointestinal reactions, and long-term use may also lead to bacterial resistance and intestinal dysbiosis.

Retinoids can be useful in cases with obvious hyperplasia, but their use is restricted by adverse effects such as xerosis and teratogenicity. Vascular-targeted agents such as hydroxychloroquine act slowly and require regular retinal monitoring. Physical treatments such as laser therapy and intense pulsed light can improve erythema and telangiectasia, but they do not control the inflammatory source of disease.

Prof. Wu summarized the limitations of traditional treatment into three major pain points in clinical practice. First, the proportion of difficult-to-treat patients is high: about 40% respond poorly to conventional therapy, especially those with persistent erythema. Second, long-term medication-related adverse effects reduce adherence and create safety concerns. Third, relapse remains common, with recurrence rates exceeding 50% within six months of drug withdrawal. These problems create a strong need for new treatment strategies that combine potent anti-inflammatory activity, barrier repair, and good long-term safety.

Precision Treatment Through Targeting the JAK-STAT Pathway

The central pathogenesis of rosacea lies in abnormal innate immunity and an amplified inflammatory loop. Research has shown that excessive activation of Toll-like receptors can trigger the JAK-STAT signaling pathway, while key inflammatory mediators such as tumor necrosis factor alpha and interleukin 6 further amplify inflammation through the same pathway, forming a vicious cycle of TLR activation, JAK-STAT activation, and cytokine release. This mechanism provides a clear therapeutic target.

On this basis, Dr. Bingyang Xu selected upadacitinib as the study drug. As a highly selective JAK1 inhibitor, upadacitinib inhibits JAK1 much more strongly than JAK2 or JAK3 and may therefore reduce the anemia and infection risk often seen with pan-JAK inhibitors. It also covers Th2-related cytokines such as IL-4 and IL-13, making it particularly suitable for patients who also have atopic dermatitis. Clinical data suggest it can control inflammation rapidly within 2 to 4 weeks, helping overcome the slow onset of traditional medications. Compared with other JAK inhibitors, tofacitinib carries a higher infection risk and baricitinib may interfere with hematopoiesis, whereas upadacitinib’s selectivity gives it a safety advantage.

The study adopted a multidimensional evaluation system combining subjective and objective measures. The Investigator Global Assessment was used to score lesion severity, the Clinician’s Erythema Assessment quantified vascular inflammation, the Patient Self-Assessment reflected subjective improvement, and the RosaQoL index assessed the disease’s impact on psychosocial quality of life. Objective endpoints included multispectral facial imaging to reduce subjective bias, as well as transepidermal water loss, skin hydration, and filaggrin measurement to evaluate skin-barrier function. This multidimensional framework helped ensure a comprehensive and scientifically robust assessment.

Marked Efficacy Across Multiple Dimensions

Dr. Xu explained that the study enrolled 12 patients with papulopustular rosacea, all of whom received upadacitinib monotherapy at 15 mg once daily for 12 weeks. This regimen was based on a solid body of prior evidence: 15 mg had already shown both efficacy and safety in atopic dermatitis studies, 12 weeks matched the usual guideline assessment window for rosacea, and animal data suggested that JAK1 inhibition can reduce cutaneous inflammation within 2 weeks.

The results were stronger than expected and broad in scope. In key efficacy measures, 83.33% of patients experienced a marked reduction in facial erythema, 91.67% improved by more than 2 points on the Investigator Global Assessment, and quality-of-life scores improved by about 62.31%, with high patient satisfaction.

Skin-barrier function also improved substantially. After treatment, filaggrin content increased by 66.56%, transepidermal water loss decreased by 23.48%, and skin hydration increased by 46.33%. These findings suggest that upadacitinib does more than improve superficial lesions. It may also repair the core skin barrier, interrupt the vicious cycle of inflammation, barrier damage, and worsening inflammation, relieve dryness and discomfort, and improve the skin’s resistance to external stimuli.

Safety was also favorable. Throughout the study, only one patient developed mild nausea, which improved after adjusting the dosing time. No infection, anemia, or other common JAK inhibitor-related adverse events occurred, supporting the good tolerability of upadacitinib at the 15 mg dose.

Prof. Wu further noted that among the four patients who also had atopic dermatitis, symptoms of both atopic dermatitis and papulopustular rosacea improved significantly after upadacitinib treatment, suggesting that the drug may have the potential to treat multiple inflammatory skin diseases simultaneously.

Precision Positioning and Future Prospects

This real-world study is the first to demonstrate that highly selective JAK1 inhibition with upadacitinib monotherapy can produce significant efficacy and good safety in papulopustular rosacea. According to Prof. Wu, the advantages appear in several scenarios. For patients who respond poorly to traditional therapy or cannot tolerate it, upadacitinib may rapidly control inflammation and improve both lesions and quality of life. For patients with severe acute inflammatory flares, it may relieve symptoms quickly while avoiding the irritation that topical agents can sometimes aggravate. For patients with comorbid inflammatory skin disorders such as atopic dermatitis, it may improve more than one disease at once and reduce treatment burden.

Prof. Wu also emphasized the limitations of the present study, including the small sample size of 12 patients and the short follow-up period of 12 weeks. Longer-term efficacy and safety remain to be confirmed. The team plans to expand the sample size, include more rosacea subtypes such as erythematotelangiectatic and phymatous forms, extend follow-up, collect data on long-term recurrence and safety, and carry out randomized controlled trials to further define the role of upadacitinib in rosacea treatment.

Conclusion

Overall, this study opens a new path for the treatment of papulopustular rosacea. Through its multidimensional benefits on lesions, barrier function, and quality of life, upadacitinib may become an important option for patients who do not do well with traditional treatment, and may offer new hope to people living with rosacea.

0
0
Loading